A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Cyclophosphamide Docetaxel Epirubicin (100) Fluorouracil Pertuzumab Trastuzumab FE100CT-HP

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL-EPIRUBICIN (100)- FLUOROURACILPERTUZUMAB-TRASTUZUMAB (FE1
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Cyclophosphamide-Docetaxel-Epirubicin-100-Fluorouracil-Pertuzumab-Trastuzumab-FE100CT-HP.pdf

Carboplatin-Pembrolizumab-Pemetrexed

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN (AUC 5)-PEMBROLIZUMAB-PEMETREXED Regimen • NSCLC – Carboplatin (AUC5)-Pembrol
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-Pembrolizumab-Pemetrexed.pdf

Cisplatin-Pembrolizumab-Pemetrexed

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-PEMBROLIZUMAB-PEMETREXED Regimen • NSCLC – Cisplatin-Pembrolizumab-Pe
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Cisplatin-Pembrolizumab-Pemetrexed.pdf

Docetaxel (75) Ver 1.1

Description
Chemotherapy Protocol BREAST CANCER DOCETAXEL (75) Regimen Breast Cancer – Docetaxel (75) Indication Trea
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Docetaxel-75-Ver-11.pdf

Carboplatin(AUC6)-Pemetrexed

Description
Chemotherapy Protocol MESOTHELIOMA CARBOPLATIN (AUC6)-PEMETREXED Regimen • Mesothelioma – Carboplatin (AUC6)-Pemetrexed Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/CarboplatinAUC6-Pemetrexed-Ver1.5.pdf

Carboplatin and Pemetrexed

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CARBOPLATIN-PEMETREXED Regimen • NSCLC – Carboplatin-Pemetrexed Indicati
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Carboplatin-Pemetrexed-Ver1.4.pdf

Docetaxel-Nintedanib v1

Description
Chemotherapy Protocol NSCLC CANCER DOCETAXEL-NINTEDANIB Regimen NSCLC – Docetaxel-Nintedanib Indication Advanced or m
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Docetaxel-Nintedanib-v1.pdf

Docetaxel

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) DOCETAXEL (75) Regimen NSCLC – Docetaxel (75) Indic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Docetaxelver12.pdf

MesoCisPemVer1.3

Description
Chemotherapy Protocol MESOTHELIOMA CISPLATIN-PEMETREXED Regimen Mesothelioma – Cisplatin-Pemetrexed Indication First line therapy of advanced pleural mesothelioma where the disease is not suitable for surgical resection WHO Performance Status 0, 1 Toxicity Drug Cisplatin Pemetrexed Adverse Effect Neuropathy, nephrotoxicity, ototoxicity Diarrhoea, skin reactions, neuropathy The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Disease A baseline chest x-ray should be performed before starting treatment and up to date (ideally within 1 month) cross section imaging should also be performed Regimen FBC, LFTs and U&Es before each cycle A chest x-ray should be performed before each cycle Consider formal audiology test if relevant Dose Modifications The dose modifications listed are for haematological, liver and renal function only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be reescalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Version 1.3 (January 2016) Page 1 of 8 Mesothelioma – Cisplatin -Pemetrexed Please discuss all dose reductions / delays with the relevant consultant before prescribing, if appropriate. The approach may be different depending on the clinical circumstances. The following is a general guide only. Haematological Prior to prescribing the following treatment criteria must be met; Criteria Neutrophil Platelets Eligible Level equal to or more than 1.5x109/L equal to or more than 100x109/L Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL Subsequently if the neutrophils are less than 1.5 x109/L, then in the first instance delay treatment for 7 days. If counts recover at this point continue at the initial dose. If counts remain low continue with treatment using a 20% dose reduction. If the myelosuppression recurs despite this dose reduction stop treatment. If the platelets are less than 100x109/L then in the first instance delay treatment for 7 days. If the counts recover at this point continue at the initial dose. If the counts still fall within this range continue using a 20% dose reduction. If the platelet level falls below 50x109/L reduce the dose by 50%. Liver Impairment Drug Adjustment Cisplatin Pemetrexed No dose adjustment required Clinical decision Renal Impairment Drug Cisplatin Pemetrexed Regimen Creatinine Clearance (ml/min) more than 60 Dose (% of original dose) 100 50-60 75 40-50 50 less than 40 Do not use Do not administer if the creatinine clearance is less than 45ml/min Version 1.3 (January 2016) Page 2 of 8 Mesothelioma – Cisplatin -Pemetrexed 21 day cycle for 3-6 cycles (6 cycles will be set in Aria) Drug Dose Days Administration Cisplatin Pemetrexed 75mg/m2 500mg/m2 Intravenous infusion in 1000ml sodium chloride 0.9% with 20mmol 1 potassium chloride at a maximum rate of 1mg cisplatin/min (minimum time 120 minutes) Intravenous infusion in 100ml 1 glucose 5% or sodium chloride 0.9% over 10 minutes Dose Information Cisplatin will be dose banded as per the CSCCN agreed bands Pemetrexed will be dose banded as per the CSCCN agreed bands Administration Information Cisplatin should be administered 30 minutes after the end of the pemetrexed infusion Pemtrexed may be administered in 100ml of either glucose 5% or sodium chloride 0.9% over 10 minutes. The choice of fluid will be dependent on the product stocked by pharmacy. The fluid and volume will not appear in the prescription but can be located in the instructions notepad Extravasation Cisplatin – exfoliant Pemetrexed - inflammitant Additional Therapy Folic acid 5mg once daily starting 1 – 2 weeks prior to and continuing for three weeks after the last dose of pemetrexed. Hydroxocobalamin intramuscular injection 1mg every three months starting 1 – 2 weeks prior to pemetrexed. Antiemetics 15-30 minutes prior to chemotherapy; - aprepitant 125mg oral - ondansetron 8mg oral or intravenous bolus Ensure the patient has taken oral dexamethasone starting the day before Version 1.3 (January 2016) Page 3 of 8 Mesothelioma – Cisplatin -Pemetrexed pemetrexed. On the occasions where individuals attend for treatment and have forgotten to take the dexamethasone pre-medication administer an intravenous bolus dose of dexamethasone 10mg 15-30 minutes before chemotherapy. As take home medication; - aprepitant 80mg once a day for 2 days oral - dexamethasone 4mg twice a day for 1 day starting the day before chemotherapy is due and dexamethasone 4mg once a day on the day of and the day after chemotherapy oral - metoclopramide 10mg three times a day when required oral - ondansetron 8mg twice a day for 3 days oral Cisplatin pre and post hydration as follows; Pre Furosemide 40mg oral or intravenous bolus 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes Post 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes Patients should be advised to drink at least 3 litres of fluid in the 24 hours after administration of cisplatin. Gastric protection with a proton pump inhibitor or a H2 antagonist may be considered in patients considered at high risk of GI ulceration or bleed Prophylactic antibiotics can be considered if required Additional Information Consideration should be given to draining pleural or peritoneal effusions prior to pemetrexed administration Coding Procurement – X71.5 Delivery – X72.1 References 1.National Institute of Clinical Excellence (2009). TA135 Pemetrexed for the treatment of mesothelioma. London: DOH. 2.Santoro A, O’Brien ME, Stahel RA et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Programme. J Thorac Oncol 2008; 3 (7): 756 – 763. Version 1.3 (January 2016) Page 4 of 8 Mesothelioma – Cisplatin -Pemetrexed REGIMEN SUMMARY Cisplatin-Pemetrexed Cycle 1, 2, 3, 4, 5 Day Minus One 1. Dexamethasone 4mg twice a day oral* Day One 2. Aprepitant 125mg oral 3. Dexamethasone 4mg once a day oral (from TTO)* 4. Ondansetron 8mg oral or intravenous bolus 5. Furosemide 40mg oral or intravenous bolus 6. 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes 7. Pemetrexed 500mg/m2 intravenous infusion in 100ml glucose 5% or sodium chloride 0.9% over 10 minutes 8. Cisplatin 75mg/m2 intravenous infusion in 1000ml sodium chloride 0.9% with 20mmol potassium chloride at a maximum rate of 1mg cisplatin/minute (minimum time 120 minutes) 9. 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes Take Home Medicines 10. Aprepitant 80mg once a day for 2 days starting on day 2 oral 11. Dexamethasone 4mg twice a day oral for 1 day starting the day before the pemetrexed infusion and 4mg once a day on the day of and the day after pemetrexed. 12. Metoclopramide 10mg three times a day when required oral 13. Ondansetron 8mg twice a day for three days starting on the evening of day 1 of the cycle oral 14. Folic acid 5mg once a day oral (continuous) Hydroxocobalamin will not be included as part of the Aria regime and must be prescribed separately on the cycle for which it is due. Version 1.3 (January 2016) Page 5 of 8 Mesothelioma – Cisplatin -Pemetrexed Cycle 6 Day Minus One 1. Dexamethasone 4mg twice a day oral* Day One 2. Aprepitant 125mg oral 3. Dexamethasone 4mg once a day oral (from TTO)* 4. Ondansetron 8mg oral or intravenous bolus 5. Furosemide 40mg oral or intravenous bolus 6. 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes 7. Pemetrexed 500mg/m2 intravenous infusion in 100ml glucose 5% or sodium chloride 0.9% over 10 minutes 8. Cisplatin 75mg/m2 intravenous infusion in 1000ml sodium chloride 0.9% with 20mmol potassium chloride at a maximum rate of 1mg cisplatin/minute (minimum time 120 minutes) 9. 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes Take Home Medicines 10. Aprepitant 80mg once a day for 2 days starting on day 2 oral 11. Metoclopramide 10mg three times a day when required oral 12. Ondansetron 8mg twice a day for three days starting on the evening of day 1 of the cycle oral 13. Folic acid 5mg once a day oral (continuous) Hydroxocobalamin will not be included as part of the Aria regime and must be prescribed separately on the cycle for which it is due. * In Aria Planner the dexamethasone 4mg twice daily will appear on days 1, and dexamethasone 4mg once a day on days 2 and 3 of treatment. This is the supply for the next cycle. The patient should have been given the supply for cycle one in the pre-assessment or consent clinic. The administration instructions reflect this. Version 1.3 (January 2016) Page 6 of 8 Mesothelioma – Cisplatin -Pemetrexed DOCUMENT CONTROL Version Date Amendment Written By Approved By 1.3 Jan 2016 Pemetrexed administration Dr Deborah Wright Donna Kimber instructions changed throughout the Pharmacist Pharmacy text Technician 1.2 Dec Header changed to NHS badge Dr Deborah Wright Liz Harrison 2013 In name “and” replaced with dash Pharmacist Pharmacist Adverse effects put in table and toxicity removed Dose modification tabulated Renal and hepatic function tabulated Clarification added on the number of cycles set in Aria Regimen tabulated Twice daily changed to twice a day Regimen name added to summary Summary re-numbered Metoclopramide dose changed to 10mg Cycle 6 added with no dexamethasone pre-med included Document control tabulated Hospital representation and disclaimer added 1.1 Sept Font changed to Arial Dr Deborah Wright Donna Kimber 2010 Header altered to include “Strength Pharmacist Pharmacy through Partnership” Technician Drug names given capitals in regimen Extravasation moved to under Administration Information Footer changed to include regimen name and review date removed Standard paragraph added to introduction in dose modifications Dose modifications format (not information) changed Administration information added Granisetron removed from antiemetics Aprepitant incorporated as per superusers Coding added Summary page added Document control added 1 Jan None Dr Deborah Wright Dr Andrew Bates 2010 Pharmacist Consultant Clinical Oncologist Dr Tim Gulliford Consultant Medical Version 1.3 (January 2016) Page 7 of 8 Mesothelioma – Cisplatin -Pemetrexed Oncologist This chemotherapy protocol has been developed as part of the chemotherapy electronic prescribing project. This was and remains a collaborative project that originated from the former CSCCN. These documents have been approved on behalf of the following Trusts; Hampshire Hospitals NHS Foundation Trust NHS Isle of Wight Portsmouth Hospitals NHS Trust Salisbury Hospitals NHS Foundation Trust University Hospital Southampton NHS Foundation Trust Western Sussex Hospitals NHS Trust All actions have been taken to ensure these protocols are correct. However, no responsibility can be taken for errors which occur as a result of following these guidelines. Version 1.3 (January 2016) Page 8 of 8 Mesothelioma – Cisplatin -Pemetrexed
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/MesoCisPemVer1.3.pdf

Docetaxel (75)-Prednisolone ver1.2

Description
Chemotherapy Protocol PROSTATE DOCETAXEL(75)-PREDNISOLONE Regimen Prostate-Docetaxel (75)-Prednisolone Indication Advanced castrate resistant prostate cancer Performance status 0, 1, 2 Toxicity Drug Docetaxel Prednisolone Adverse Effect Hypersensitivity, fluid retention, neuropathy, joint pains, nail changes, fatigue Weight gain, GI disturbances, hyperglycaemia, CNS disturbances, cushingoid changes, osteoporosis The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Drugs FBC, LFTs, PSA and U&Es prior to each cycle Dose Modifications The dose modifications listed are for haematological, liver and renal function and drug specific toxicities only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re-escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Please discuss all dose reductions / delays with the relevant consultant before prescribing, if appropriate. The approach may be different depending on the clinical circumstances. Version 1.2 (May 2015) Page 1 of 7 Prostate-Docetaxel(75)-Prednisolone Haematological Consider a blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL. Prior to cycle one the following criteria should be met; Criteria Neutrophils Platelets Eligible Level 1x109/L or greater 50x109/L or greater Dose modifications based on haematological parameters apply to docetaxel only. Neutrophils (x109/L) 1 or greater less than 1 on the day of treatment or less than 1 with fever/infection at any time or less than 0.5 for more than 7 days Platelets (x109/L) 50 or greater less than 50 Dose Modifications (docetaxel) 100% 1st Occurrence Delay until recovery to 1x109/L or greater and then give 60mg/m2 2nd Occurrence Delay until recovery to 1x109/L or greater then give 45mg/m2 Dose Modifications (docetaxel) 100% 1st Occurrence Delay until recovery to 50x109/L or greater then give 60mg/m2 2nd Occurrence Delay until recovery to 50x109/L or greater then give 45mg/m2 Hepatic Impairment Consider weekly scheduling if there is a mild or moderate hepatic impairment Drug Bilirubin (μmol/L) AST/ALT (units/L) Alk Phos Dose (units/L) (% of original dose) N/A greater than 1.5xULN and greater than 2.5xULN Docetaxel greater than ULN and/ or greater than 3.5xULN and greater than 6xULN Give 75% Not Recommended Renal Impairment Drug Docetaxel Creatinine Clearance (ml/min) N/A Dose (% of original dose) No dose adjustment needed Version 1.2 (May 2015) Page 2 of 7 Prostate-Docetaxel(75)-Prednisolone Other Dose reductions or interruptions in therapy are not necessary for those toxicities that are considered unlikely to be serious or life threatening. For example, alopecia, altered taste or nail changes. For all other non-haematological NCI-CTC grade 3 and above toxicities delay treatment until the adverse effect has resolved to NCI-CTC grade 1 or below. The dose should then be reduced to 60mg/m2 or discontinued as appropriate. The following recommendations apply to docetaxel only. The prednisolone should be continued if the docetaxel is delayed. It should be stopped if the docetaxel is stopped but may require a reducing schedule. Peripheral Neuropathy Peripheral neuropathy at NCI-CTC grade 3 should result in a dose reduction from 75mg/m2 to 60mg/m2 once the neuropathy has resolved to NCI-CTC grade 2 or below. If the NCI-CTC grade 3 neuropathy occurred at doses lower than 75mg/m2 or a NCI-CTC grade 4 toxicity develops consider stopping treatment. Lacrimation Excessive lacrimation is related to cumulative docetaxel doses and occurs after a median of 400mg/m². Symptomatic treatment with hypromellose 0.3% eye drops four times a day may help. However, if the ocular irritation continues reduce the docetaxel dose to 60mg/m2. Skin Delay the docetaxel where a NCI-CTC grade 3 cutaneous toxicity is present on day one of the cycle until it resolves to NCI-CTC grade 1 or below. The subsequent doses of docetaxel should be reduced from 75mg/m2 to 60mg/m2. If it occurs with a dose of 60mg/m2 or if there is no recovery after two weeks, docetaxel treatment should be stopped. Where a NCI-CTC grade 3 cutaneous toxicity occurs between cycles with recovery by day one then reduce the docetaxel dose as described. Docetaxel should be stopped in response to a NCI-CTC grade 4 cutaneous toxicity. Stomatitis A NCI-CTC grade 2 stomatitis should result in a delay in treatment until it has become NCICTC grade 1 or below. Treatment may then be re-started at the previous dose. For a NCICTC grade 3 stomatitis delay treatment until it has recovered to NCI-CTC grade 1 or below then reduce the dose to 60mg/m2. Treatment should be stopped in relation to a NCI-CTC grade 4 stomatitis. Version 1.2 (May 2015) Page 3 of 7 Prostate-Docetaxel(75)-Prednisolone Regimen Docetaxel is highly myelosuppressive and in those with poor bone marrow reserves (for example due to extensive prior treatment, bone metastasis or extensive skeletal radiation) consider a starting dose of 60mg/m² with a view to increase to 75mg/m² if well tolerated. 21 day cycle for up to 10 cycles Drug Docetaxel Prednisolone Dose 75mg/m2 5mg twice a day Days 1 Administration Intravenous infusion in 250ml sodium chloride 0.9% over 60 minutes 1-21 incl. Oral Dose Information Docetaxel will be banded as per the CSCCN agreed bands. Docetaxel induced fluid retention can lead to weight gain. This is not a reason to alter the doses Docetaxel doses of more than 200mg should be diluted in 500ml sodium chloride 0.9% (maximum concentration 0.74mg/ml) Prednisolone is available as 5mg (uncoated) and 2.5mg and 5mg (enteric coated) tablets. Administration Information Docetaxel hypersensitivity reactions tend to occur with the first or second infusion. For minor symptoms such as flushing or localised rashes the infusion should not be interrupted. For severe reactions including profound hypotension, bronchospasm and generalised erythema discontinue the infusion immediately. Prednisolone should be taken with or after food. Extravasation Docetaxel - exfoliant Additional Therapy Premedication - dexamethasone 8mg oral at 12 hours, 3 hours and 1 hour prior to docetaxel Antiemetics 15-30 minutes prior to chemotherapy - metoclopramide 10mg oral or intravenous Version 1.2 (May 2015) Page 4 of 7 Prostate-Docetaxel(75)-Prednisolone As take home medication - metoclopramide 10mg oral three times a day for 3 days then as required Coding (OPCS) Procurement – X71.1 Delivery – X72.3 References 1.Tannock IF, deWit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512. 2.NICE Guidance TA101. Docetaxel for the treatment of hormone refractory metastatic prostate cancer; June 2006. 3.STAMPEDE trial protocol. Version 7.1. 21st June 201 Version 1.2 (May 2015) Page 5 of 7 Prostate-Docetaxel(75)-Prednisolone REGIMEN SUMMARY Docetaxel (75)-Prednisolone Cycles 1, 2, 3, 4, 5, 6, 7, 8, 9 Day minus 1 1. Dexamethasone 8mg oral at 12 hours, 3 hours and 1 hour prior to docetaxel (from TTO)* Day 1 2. Dexamethasone from TTO (see above)* 3. Metoclopramide 10mg oral or intravenous 4. Docetaxel 75mg/m2 in 250ml sodium chloride 0.9% intravenous infusion over 60 minutes Administration Instructions Ensure the patient has taken the dexamethasone pre-medication prior to treatment. On the occasions where individuals attend for treatment and have forgotten to take the dexamethasone premedication administer dexamethasone 20mg intravenous stat 15-30 minutes prior to chemotherapy Take Home Medicines 5. Prednisolone 5mg twice a day oral for 21 days Administration Instructions Take with or after food. The dose of this medicine may need to be reduced gradually before stopping treatment. 6. Dexamethasone 8mg oral at 12 hours, 3 hours and 1 hour prior to docetaxel 7. Metoclopramide 10mg oral three times a day for 3 days then 10mg three times a day when required for nausea. Cycle 10 Day minus 1 8. Dexamethasone 8mg oral at 12 hours, 3 hours and 1 hour prior to docetaxel (from TTO)* Day 1 9. Dexamethasone from TTO (see above)* 10. Metoclopramide 10mg oral or intravenous 11. Docetaxel 75mg/m2 in 250ml sodium chloride 0.9% intravenous infusion over 60 minutes Administration Instructions Ensure the patient has taken the dexamethasone pre-medication prior to treatment. On the occasions where individuals attend for treatment and have forgotten to take the dexamethasone premedication administer dexamethasone 20mg intravenous stat 15-30 minutes prior to chemotherapy Take Home Medicines 12. Prednisolone 5mg twice a day oral for 21 days Administration Instructions Take with or after food. The dose of this medicine may need to be reduced gradually before stopping treatment. 13. Metoclopramide 10mg oral three times a day for 3 days then 10mg three times a day when required for nausea. * In Aria Planner the dexamethasone TTO will appear on day 1 of treatment. This is the supply for the next cycle. Version 1.2 (May 2015) Page 6 of 7 Prostate-Docetaxel(75)-Prednisolone DOCUMENT CONTROL Version Date Amendment Written By Approved By Header changed Metoclopramide dose changed to 10mg Bolus removed from intravenous bolus throughout text Hepatic dose modification table 1.2 May 2015 updated Docetaxel admin instructions added Donna Kimber Pharmacy Technician Dexamethasone TTO updated Prednisolone admin instructions updated OPCS codes updated Disclaimer added Dexamethasone changed to dexamethasone 8mg oral twice 1.1 May 2013 a day the day before, the day of and the day after docetaxel in Dr Debbie Wright Pharmacist additional therapy section and also treatment summary. 1 Jan 2013 None Rebecca Wills Pharmacist Dr Debbie Wright Pharmacist Rebecca Wills Pharmacist Dr Mathew Wheater Consultant Medical Oncologist Dr Joanna Gale Consultant Medical Oncologist Dr Mathew Wheater Consultant Medical Oncologist This chemotherapy protocol has been developed as part of the chemotherapy electronic prescribing project. This was and remains a collaborative project that originated from the former CSCCN. These documents have been approved on behalf of the following Trusts; Hampshire Hospitals NHS Foundation Trust NHS Isle of Wight Portsmouth Hospitals NHS Trust Salisbury Hospitals NHS Foundation Trust University Hospital Southampton NHS Foundation Trust Western Sussex Hospitals NHS Foundation Trust All actions have been taken to ensure these protocols are correct. However, no responsibility can be taken for errors which occur as a result of following these guidelines. Version 1.2 (May 2015) Page 7 of 7 Prostate-Docetaxel(75)-Prednisolone
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Docetaxel-75-Prednisolone-ver1.2.pdf
1 to 10 of 30
Previous 1 2 3 Next